Varex Imaging Corp (VREX)
As-reported financials and SEC filings for Varex Imaging Corp. The latest annual period is FY2025. The latest reported quarter is Q3 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Varex Imaging Corp
Varex Imaging Corp designs, manufactures, and sells X-ray imaging components and systems used in medical diagnostic imaging, security inspection, and industrial quality inspection. Its products include X-ray tubes, flat panel and photon counting detectors, image processing software, and linear accelerators. The company serves original equipment manufacturers (OEMs) globally, supplying components for medical modalities like CT and mammography, as well as industrial applications such as cargo screening and non-destructive testing.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended October 3, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Varex Imaging
- Revenue grew 4.1% to $845M in FY2025, after a 9.2% decline the year before.
- Operating margin is now a 3.3% loss in FY2025, from 9.1% in FY2021.
- Most recent quarter Q3 FY2026: revenue $211M, up 3.7% from Q3 FY2025.
- Free cash flow was $19M in FY2025, 2.2% of revenue.
- Net loss widened to $70M in FY2025, from $49M in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Varex Imaging’s fundamentals sit among the 625 Technology companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 1 of the superinvestors we track (plus 7 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| D. E. Shawquant | Q2 2026 | $9.7M | 925.3K | Reduced |
| AQR Capital Managementquant | Q2 2026 | $4.9M | 468.6K | Reduced |
| Two Sigma Investmentsquant | Q2 2026 | $4.8M | 463.1K | Reduced |
| Citadel Advisorsquant | Q2 2026 | $3.7M | 353.5K | Added |
| Renaissance Technologiesquant | Q2 2026 | $2.7M | 258.5K | Reduced |
| First Eagle Investment Management | Q2 2026 | $1.9M | 179.5K | New |
| Point72 Asset Managementquant | Q2 2026 | $1.8M | 173.7K | Added |
| Millennium Managementquant | Q2 2026 | $1.4M | 133.7K | Added |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 1.5M | +23.8% | 1.00 |
| 2026-07-31 | 1.2M | +2.2% | 3.89 |
| 2026-07-15 | 1.2M | -7.5% | 3.02 |
| 2026-06-30 | 1.3M | +3.3% | 2.20 |
| 2026-06-15 | 1.3M | +7.8% | 3.41 |
| 2026-05-29 | 1.2M | -9.0% | 3.11 |
| 2026-05-15 | 1.3M | -19.1% | 2.04 |
| 2026-04-30 | 1.6M | +15.8% | 5.57 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $844.6M | $811.0M | $893.4M | $859.4M | $818.1M |
| Gross profit | $290.5M | $256.9M | $290.3M | $283.5M | $271.5M |
| Operating income | $-27.8M | $32.1M | $77.1M | $88.2M | $74.1M |
| Net income | $-70.3M | $-48.8M | $47.4M | $30.3M | $17.4M |
| Diluted EPS | $-1.70 | $-1.20 | $1.07 | $0.73 | $0.43 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $145.0M | $168.7M | $152.6M | $89.4M | $144.6M |
| Current assets | $641.8M | $649.9M | $658.3M | $609.9M | $554.2M |
| Total assets | $1.11B | $1.21B | $1.25B | $1.18B | $1.15B |
| Current liabilities | $187.2M | $195.9M | $162.8M | $173.1M | $166.6M |
| Long-term debt | $366.0M | $397.1M | $441.1M | $412.3M | $431.7M |
| Total liabilities | $620.8M | $670.4M | $668.6M | $637.7M | $651.0M |
| Total equity | $486.6M | $543.2M | $581.0M | $546.7M | $496.5M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $41.7M | $47.3M | $108.4M | $16.9M | $92.6M |
| Capital expenditure | $22.9M | $26.9M | $20.7M | $21.3M | $15.1M |
| Free cash flow | $18.8M | $20.4M | $87.7M | $-4.4M | $77.5M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | $210.5M | 3.7% | $15.7M | $0.37 |
| Q2 FY2026 | $216.0M | 1.5% | $-8.1M | $-0.19 |
| Q1 FY2026 | $209.6M | 4.9% | $2.3M | $0.05 |
| Q4 FY2025 | $228.9M | 11.3% | $12.2M | $0.29 |
| Q3 FY2025 | $203.0M | -2.9% | $-89.1M | $-2.15 |
| Q2 FY2025 | $212.9M | 3.2% | $6.9M | $0.17 |
| Q1 FY2025 | $199.8M | 5.2% | $-300,000 | $-0.01 |
| Q4 FY2024 | $205.7M | -9.5% | $-51.1M | $-1.29 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest Technology peers
Monitor VREX
Get an alert when Varex Imaging files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor VREX freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.